Showing results (1-10 of 394) with videos related to
Sort By:
Pageof 40
Developmental Pharmacology and Therapeutics|January 1, 1989
Anticancer therapy as a pediatric pharmacodynamic paradigmW E Evans, M V Relling, J H Rodman, et al.The New England Journal of Medicine|February 19, 1998
Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemiaW E Evans, M V Relling, J H Rodman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994
Patient characteristics associated with high-risk methotrexate concentrations and toxicityM V Relling, D Fairclough, D Ayers, et al.Pediatric Clinics of North America|October 1, 1989
Clinical pharmacology of cancer chemotherapy in childrenW E Evans, W P Petros, M V Relling, et al.Medical and Pediatric Oncology|January 1, 1991
Concept of maximum tolerated systemic exposure and its application to phase I-II studies of anticancer drugsW E Evans, J H Rodman, M V Relling, et al.Journal of Pharmaceutical Sciences|June 1, 1989
Hepatic drug clearance in children: studies with indocyanine green as a model substrateW E Evans, M V Relling, S de Graaf, et al.Seminars in Oncology|February 1, 1993
Clinical pharmacokinetics and pharmacodynamics of anticancer drugs in childrenJ H Rodman, M V Relling, C F Stewart, et al.The British Journal of Cancer. Supplement|August 1, 1992
Disposition of antineoplastic agents in the very young childH L McLeod, M V Relling, W R Crom, et al.Clinical Pharmacokinetics|March 1, 1987
Pharmacokinetics of anticancer drugs in childrenW R Crom, A M Glynn-Barnhart, J H Rodman, et al.Clinical Pharmacology and Therapeutics|August 1, 1991
Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrineW R Crom, M V Relling, M L Christensen, et al.Pageof 40